Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Other Accumulated Expenses (2016 - 2025)

Haemonetics has reported Other Accumulated Expenses over the past 16 years, most recently at $134.3 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 3.52% year-over-year to $134.3 million; the TTM value through Dec 2025 reached $134.3 million, down 3.52%, while the annual FY2025 figure was $148.1 million, 8.85% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $134.3 million at Haemonetics, roughly flat from $134.0 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $150.0 million in Q3 2024 and troughed at $85.3 million in Q3 2022.
  • A 5-year average of $125.9 million and a median of $130.1 million in 2021 define the central range for Other Accumulated Expenses.
  • Biggest five-year swings in Other Accumulated Expenses: skyrocketed 41.93% in 2021 and later plummeted 33.26% in 2022.
  • Year by year, Other Accumulated Expenses stood at $119.7 million in 2021, then fell by 15.63% to $101.0 million in 2022, then surged by 31.12% to $132.4 million in 2023, then increased by 5.15% to $139.2 million in 2024, then decreased by 3.52% to $134.3 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for HAE at $134.3 million in Q4 2025, $134.0 million in Q3 2025, and $145.6 million in Q2 2025.